These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W. Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781 [Abstract] [Full Text] [Related]
30. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Coffee AL, Sulak PJ, Kuehl TJ. Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150 [Abstract] [Full Text] [Related]
31. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Vercellini P, Barbara G, Somigliana E, Bianchi S, Abbiati A, Fedele L. Fertil Steril; 2010 May 01; 93(7):2150-61. PubMed ID: 19328469 [Abstract] [Full Text] [Related]
32. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Milsom I, Lete I, Bjertnaes A, Rokstad K, Lindh I, Gruber CJ, Birkhäuser MH, Aubeny E, Knudsen T, Bastianelli C. Hum Reprod; 2006 Sep 01; 21(9):2304-11. PubMed ID: 16763008 [Abstract] [Full Text] [Related]
37. Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives. Hamerlynck JV, Vollebregt JA, Doornebos CM, Muntendam P. Contraception; 1987 Mar 01; 35(3):199-205. PubMed ID: 2956054 [Abstract] [Full Text] [Related]